Search

Search Constraints

You searched for: Author/Creator Lefkowitz, Martin

Search Results

1. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. (28th March 2020)

2. Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection Fraction. Issue 18 (27th August 2022)

3. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). (3rd June 2014)

4. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. (17th March 2021)

5. Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM‐HF analysis. (9th March 2021)

6. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Issue 5 (May 2017)

7. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial. (10th June 2016)

8. Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482‐489]. (20th June 2016)

9. Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482‐489]. (June 2016)

10. Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. (November 2016)